#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4 .
1-1	0-1	4	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=Considering the properties and biological role of silicon , we evaluated the effects of nutritional supplementation with silicon-enriched spirulina on vascular remodeling induced by hypertension in a SHR rat model .
3-1	15-26	Considering	_	_	_	_
3-2	27-30	the	abstract[3]	new[3]	_	_
3-3	31-41	properties	abstract[3]	new[3]	_	_
3-4	42-45	and	_	_	_	_
3-5	46-56	biological	abstract[4]	new[4]	coref	23-20[169_4]
3-6	57-61	role	abstract[4]	new[4]	_	_
3-7	62-64	of	abstract[4]	new[4]	_	_
3-8	65-72	silicon	abstract[4]|substance	new[4]|new	_	_
3-9	73-74	,	_	_	_	_
3-10	75-77	we	person	acc	ana	4-1
3-11	78-87	evaluated	_	_	_	_
3-12	88-91	the	abstract[7]	new[7]	coref	4-4[17_7]
3-13	92-99	effects	abstract[7]	new[7]	_	_
3-14	100-102	of	abstract[7]	new[7]	_	_
3-15	103-114	nutritional	abstract[7]|substance[8]	new[7]|new[8]	coref	7-6[38_8]
3-16	115-130	supplementation	abstract[7]|substance[8]	new[7]|new[8]	_	_
3-17	131-135	with	abstract[7]|substance[8]	new[7]|new[8]	_	_
3-18	136-152	silicon-enriched	abstract[7]|substance[8]|substance[9]	new[7]|new[8]|new[9]	_	_
3-19	153-162	spirulina	abstract[7]|substance[8]|substance[9]	new[7]|new[8]|new[9]	_	_
3-20	163-165	on	abstract[7]|substance[8]|substance[9]	new[7]|new[8]|new[9]	_	_
3-21	166-174	vascular	abstract[7]|substance[8]|substance[9]|event[10]	new[7]|new[8]|new[9]|new[10]	coref	5-14[29_10]
3-22	175-185	remodeling	abstract[7]|substance[8]|substance[9]|event[10]	new[7]|new[8]|new[9]|new[10]	_	_
3-23	186-193	induced	_	_	_	_
3-24	194-196	by	_	_	_	_
3-25	197-209	hypertension	abstract	new	coref	11-27
3-26	210-212	in	_	_	_	_
3-27	213-214	a	abstract[14]	new[14]	_	_
3-28	215-218	SHR	object|abstract[14]	new|new[14]	coref	5-22
3-29	219-222	rat	animal|abstract[14]	new|new[14]	_	_
3-30	223-228	model	abstract[14]	new[14]	_	_
3-31	229-230	.	_	_	_	_

#Text=Our study showed highly beneficial effects including attenuation of arterial pressure and improvement of vascular reactivity .
4-1	231-234	Our	person|abstract[16]	giv|new[16]	ana|ana	13-3|13-3
4-2	235-240	study	abstract[16]	new[16]	_	_
4-3	241-247	showed	_	_	_	_
4-4	248-254	highly	abstract[17]	giv[17]	_	_
4-5	255-265	beneficial	abstract[17]	giv[17]	_	_
4-6	266-273	effects	abstract[17]	giv[17]	_	_
4-7	274-283	including	abstract[17]	giv[17]	_	_
4-8	284-295	attenuation	abstract[17]|abstract[18]	giv[17]|new[18]	_	_
4-9	296-298	of	abstract[17]|abstract[18]	giv[17]|new[18]	_	_
4-10	299-307	arterial	abstract[17]|abstract[18]|substance|abstract[20]	giv[17]|new[18]|new|new[20]	coref|coref	5-8|5-8
4-11	308-316	pressure	abstract[17]|abstract[18]|abstract[20]	giv[17]|new[18]|new[20]	_	_
4-12	317-320	and	abstract[17]|abstract[18]	giv[17]|new[18]	_	_
4-13	321-332	improvement	abstract[17]|abstract[18]|abstract[21]	giv[17]|new[18]|new[21]	_	_
4-14	333-335	of	abstract[17]|abstract[18]|abstract[21]	giv[17]|new[18]|new[21]	_	_
4-15	336-344	vascular	abstract[17]|abstract[18]|abstract[21]|abstract[22]	giv[17]|new[18]|new[21]|new[22]	_	_
4-16	345-355	reactivity	abstract[17]|abstract[18]|abstract[21]|abstract[22]	giv[17]|new[18]|new[21]|new[22]	_	_
4-17	356-357	.	_	_	_	_

#Text=These benefits were associated with reduction in arterial thickness and stiffness caused by the structural remodeling of the aortic wall in SHR .
5-1	358-363	These	abstract[23]	new[23]	_	_
5-2	364-372	benefits	abstract[23]	new[23]	_	_
5-3	373-377	were	_	_	_	_
5-4	378-388	associated	_	_	_	_
5-5	389-393	with	_	_	_	_
5-6	394-403	reduction	abstract[24]	new[24]	coref	11-6[66_24]
5-7	404-406	in	abstract[24]	new[24]	_	_
5-8	407-415	arterial	abstract[24]|quantity|abstract[26]|abstract[27]	new[24]|giv|new[26]|new[27]	ana|coref|ana|coref|ana|coref	6-1[0_27]|9-9|6-1[0_27]|9-9|6-1[0_27]|9-9
5-9	416-425	thickness	abstract[24]|abstract[26]|abstract[27]	new[24]|new[26]|new[27]	_	_
5-10	426-429	and	abstract[24]|abstract[27]	new[24]|new[27]	_	_
5-11	430-439	stiffness	abstract[24]|abstract[27]|abstract	new[24]|new[27]|new	coref	11-3[65_0]
5-12	440-446	caused	_	_	_	_
5-13	447-449	by	_	_	_	_
5-14	450-453	the	event[29]	giv[29]	coref	11-23[72_29]
5-15	454-464	structural	event[29]	giv[29]	_	_
5-16	465-475	remodeling	event[29]	giv[29]	_	_
5-17	476-478	of	event[29]	giv[29]	_	_
5-18	479-482	the	event[29]|object[31]	giv[29]|new[31]	coref	14-9[0_31]
5-19	483-489	aortic	event[29]|place|object[31]	giv[29]|new|new[31]	coref	21-3
5-20	490-494	wall	event[29]|object[31]	giv[29]|new[31]	_	_
5-21	495-497	in	event[29]|object[31]	giv[29]|new[31]	_	_
5-22	498-501	SHR	event[29]|object[31]|abstract	giv[29]|new[31]|giv	coref	13-19
5-23	502-503	.	_	_	_	_

#Text=They were mainly attributable to Si enrichment .
6-1	504-508	They	abstract	giv	_	_
6-2	509-513	were	_	_	_	_
6-3	514-520	mainly	_	_	_	_
6-4	521-533	attributable	_	_	_	_
6-5	534-536	to	_	_	_	_
6-6	537-539	Si	person|abstract[35]	new|new[35]	coref|coref	28-29|28-29
6-7	540-550	enrichment	abstract[35]	new[35]	_	_
6-8	551-552	.	_	_	_	_

#Text=Beneficial and safe effects of SpSi supplementation were previously reported in high fat diet-induced models of atherosclerosis in hamsters and metabolic syndrome in rats .
7-1	553-563	Beneficial	abstract[36]	new[36]	coref	9-6[56_36]
7-2	564-567	and	abstract[36]	new[36]	_	_
7-3	568-572	safe	abstract[36]	new[36]	_	_
7-4	573-580	effects	abstract[36]	new[36]	_	_
7-5	581-583	of	abstract[36]	new[36]	_	_
7-6	584-588	SpSi	abstract[36]|substance|substance[38]	new[36]|new|giv[38]	coref|coref|coref|coref	8-14[52_0]|8-17[54_38]|8-14[52_0]|8-17[54_38]
7-7	589-604	supplementation	abstract[36]|substance[38]	new[36]|giv[38]	_	_
7-8	605-609	were	_	_	_	_
7-9	610-620	previously	_	_	_	_
7-10	621-629	reported	_	_	_	_
7-11	630-632	in	_	_	_	_
7-12	633-637	high	substance[39]	new[39]	_	_
7-13	638-641	fat	substance[39]	new[39]	_	_
7-14	642-654	diet-induced	abstract[40]	new[40]	_	_
7-15	655-661	models	abstract[40]	new[40]	_	_
7-16	662-664	of	abstract[40]	new[40]	_	_
7-17	665-680	atherosclerosis	abstract[40]|abstract[41]	new[40]|new[41]	_	_
7-18	681-683	in	abstract[40]|abstract[41]	new[40]|new[41]	_	_
7-19	684-692	hamsters	abstract[40]|abstract[41]|animal	new[40]|new[41]|new	_	_
7-20	693-696	and	abstract[40]|abstract[41]	new[40]|new[41]	_	_
7-21	697-706	metabolic	abstract[40]|abstract[41]|person|abstract[44]	new[40]|new[41]|new|new[44]	_	_
7-22	707-715	syndrome	abstract[40]|abstract[41]|abstract[44]	new[40]|new[41]|new[44]	_	_
7-23	716-718	in	abstract[40]|abstract[41]|abstract[44]	new[40]|new[41]|new[44]	_	_
7-24	719-723	rats	abstract[40]|abstract[41]|abstract[44]|animal	new[40]|new[41]|new[44]|new	_	_
7-25	724-725	.	_	_	_	_

#Text=Improvement of glucose tolerance , insulin resistance , or dyslipidemia were evidenced with both SpSi and Sp supplementation .
8-1	726-737	Improvement	abstract[46]	new[46]	_	_
8-2	738-740	of	abstract[46]	new[46]	_	_
8-3	741-748	glucose	abstract[46]|substance|abstract[48]	new[46]|new|new[48]	_	_
8-4	749-758	tolerance	abstract[46]|abstract[48]	new[46]|new[48]	_	_
8-5	759-760	,	abstract[46]	new[46]	_	_
8-6	761-768	insulin	abstract[46]|event|abstract[50]	new[46]|new|new[50]	_	_
8-7	769-779	resistance	abstract[46]|abstract[50]	new[46]|new[50]	_	_
8-8	780-781	,	abstract[46]	new[46]	_	_
8-9	782-784	or	abstract[46]	new[46]	_	_
8-10	785-797	dyslipidemia	abstract[46]|abstract	new[46]|new	_	_
8-11	798-802	were	_	_	_	_
8-12	803-812	evidenced	_	_	_	_
8-13	813-817	with	_	_	_	_
8-14	818-822	both	substance[52]	giv[52]	coref	9-4[0_52]
8-15	823-827	SpSi	substance[52]	giv[52]	_	_
8-16	828-831	and	_	_	_	_
8-17	832-834	Sp	abstract|substance[54]	new|giv[54]	coref|coref|coref|coref	20-5[0_54]|28-11|20-5[0_54]|28-11
8-18	835-850	supplementation	substance[54]	giv[54]	_	_
8-19	851-852	.	_	_	_	_

#Text=However , only SpSi had beneficial effects on arterial function .
9-1	853-860	However	_	_	_	_
9-2	861-862	,	_	_	_	_
9-3	863-867	only	_	_	_	_
9-4	868-872	SpSi	substance	giv	coref	10-7
9-5	873-876	had	_	_	_	_
9-6	877-887	beneficial	abstract[56]	giv[56]	_	_
9-7	888-895	effects	abstract[56]	giv[56]	_	_
9-8	896-898	on	abstract[56]	giv[56]	_	_
9-9	899-907	arterial	abstract[56]|substance|abstract[58]	giv[56]|giv|new[58]	coref|coref|coref|coref	14-8|19-28[138_58]|14-8|19-28[138_58]
9-10	908-916	function	abstract[56]|abstract[58]	giv[56]|new[58]	_	_
9-11	917-918	.	_	_	_	_

#Text=No toxicity or side effects of SpSi supplement were otherwise observed .
10-1	919-921	No	abstract[59]	new[59]	_	_
10-2	922-930	toxicity	abstract[59]	new[59]	_	_
10-3	931-933	or	_	_	_	_
10-4	934-938	side	abstract|abstract[61]	new|new[61]	_	_
10-5	939-946	effects	abstract[61]	new[61]	_	_
10-6	947-949	of	abstract[61]	new[61]	_	_
10-7	950-954	SpSi	abstract[61]|substance|substance[63]	new[61]|giv|new[63]	coref|coref	13-8[84_0]|13-8[84_0]
10-8	955-965	supplement	abstract[61]|substance[63]	new[61]|new[63]	_	_
10-9	966-970	were	_	_	_	_
10-10	971-980	otherwise	_	_	_	_
10-11	981-989	observed	_	_	_	_
10-12	990-991	.	_	_	_	_

#Text=Increase of arterial stiffness , reduction of arterial compliance , and distensibility marked by fragmentation of elastin are the main consequences of arterial remodeling occurring in hypertension , obesity and aging .
11-1	992-1000	Increase	abstract[64]	new[64]	coref	11-19[71_64]
11-2	1001-1003	of	abstract[64]	new[64]	_	_
11-3	1004-1012	arterial	abstract[64]|abstract[65]	new[64]|giv[65]	_	_
11-4	1013-1022	stiffness	abstract[64]|abstract[65]	new[64]|giv[65]	_	_
11-5	1023-1024	,	abstract[64]	new[64]	_	_
11-6	1025-1034	reduction	abstract[64]|abstract[66]	new[64]|giv[66]	coref	12-12[79_66]
11-7	1035-1037	of	abstract[64]|abstract[66]	new[64]|giv[66]	_	_
11-8	1038-1046	arterial	abstract[64]|abstract[66]|abstract[67]	new[64]|giv[66]|new[67]	coref	15-12[0_67]
11-9	1047-1057	compliance	abstract[64]|abstract[66]|abstract[67]	new[64]|giv[66]|new[67]	_	_
11-10	1058-1059	,	abstract[64]	new[64]	_	_
11-11	1060-1063	and	abstract[64]	new[64]	_	_
11-12	1064-1078	distensibility	abstract[64]|abstract	new[64]|new	coref	15-14
11-13	1079-1085	marked	_	_	_	_
11-14	1086-1088	by	_	_	_	_
11-15	1089-1102	fragmentation	abstract[69]	new[69]	coref	14-15[0_69]
11-16	1103-1105	of	abstract[69]	new[69]	_	_
11-17	1106-1113	elastin	abstract[69]|substance	new[69]|new	coref	12-14
11-18	1114-1117	are	_	_	_	_
11-19	1118-1121	the	abstract[71]	giv[71]	_	_
11-20	1122-1126	main	abstract[71]	giv[71]	_	_
11-21	1127-1139	consequences	abstract[71]	giv[71]	_	_
11-22	1140-1142	of	abstract[71]	giv[71]	_	_
11-23	1143-1151	arterial	abstract[71]|event[72]	giv[71]|giv[72]	coref	12-1[76_72]
11-24	1152-1162	remodeling	abstract[71]|event[72]	giv[71]|giv[72]	_	_
11-25	1163-1172	occurring	_	_	_	_
11-26	1173-1175	in	_	_	_	_
11-27	1176-1188	hypertension	abstract	giv	coref	12-4
11-28	1189-1190	,	_	_	_	_
11-29	1191-1198	obesity	abstract	new	_	_
11-30	1199-1202	and	_	_	_	_
11-31	1203-1208	aging	abstract	new	_	_
11-32	1209-1210	.	_	_	_	_

#Text=Vascular remodeling in hypertension is characterized by altered ultrastructure due to reduction in elastin and increase in fibrous tissue .
12-1	1211-1219	Vascular	event[76]	giv[76]	coref	23-5[164_76]
12-2	1220-1230	remodeling	event[76]	giv[76]	_	_
12-3	1231-1233	in	event[76]	giv[76]	_	_
12-4	1234-1246	hypertension	event[76]|abstract	giv[76]|giv	coref	15-17
12-5	1247-1249	is	_	_	_	_
12-6	1250-1263	characterized	_	_	_	_
12-7	1264-1266	by	_	_	_	_
12-8	1267-1274	altered	abstract[78]	new[78]	_	_
12-9	1275-1289	ultrastructure	abstract[78]	new[78]	_	_
12-10	1290-1293	due	_	_	_	_
12-11	1294-1296	to	_	_	_	_
12-12	1297-1306	reduction	abstract[79]	giv[79]	_	_
12-13	1307-1309	in	abstract[79]	giv[79]	_	_
12-14	1310-1317	elastin	abstract[79]|substance	giv[79]|giv	coref	16-18
12-15	1318-1321	and	_	_	_	_
12-16	1322-1330	increase	_	_	_	_
12-17	1331-1333	in	_	_	_	_
12-18	1334-1341	fibrous	object[81]	new[81]	_	_
12-19	1342-1348	tissue	object[81]	new[81]	_	_
12-20	1349-1350	.	_	_	_	_

#Text=Here , we assessed the effect of SpSi on the ultrastructural , mechanical and functional changes characterized in SHR thoracic aorta .
13-1	1351-1355	Here	_	_	_	_
13-2	1356-1357	,	_	_	_	_
13-3	1358-1360	we	person	giv	ana	16-7
13-4	1361-1369	assessed	_	_	_	_
13-5	1370-1373	the	abstract[83]	new[83]	_	_
13-6	1374-1380	effect	abstract[83]	new[83]	_	_
13-7	1381-1383	of	abstract[83]	new[83]	_	_
13-8	1384-1388	SpSi	abstract[83]|substance[84]	new[83]|giv[84]	coref	20-7[0_84]
13-9	1389-1391	on	abstract[83]|substance[84]	new[83]|giv[84]	_	_
13-10	1392-1395	the	abstract[83]|substance[84]|abstract[85]	new[83]|giv[84]|new[85]	coref	15-1[99_85]
13-11	1396-1411	ultrastructural	abstract[83]|substance[84]|abstract[85]	new[83]|giv[84]|new[85]	_	_
13-12	1412-1413	,	abstract[83]|substance[84]|abstract[85]	new[83]|giv[84]|new[85]	_	_
13-13	1414-1424	mechanical	abstract[83]|substance[84]|abstract[85]	new[83]|giv[84]|new[85]	_	_
13-14	1425-1428	and	abstract[83]|substance[84]|abstract[85]	new[83]|giv[84]|new[85]	_	_
13-15	1429-1439	functional	abstract[83]|substance[84]|abstract[85]	new[83]|giv[84]|new[85]	_	_
13-16	1440-1447	changes	abstract[83]|substance[84]|abstract[85]	new[83]|giv[84]|new[85]	_	_
13-17	1448-1461	characterized	_	_	_	_
13-18	1462-1464	in	_	_	_	_
13-19	1465-1468	SHR	abstract|object[87]	giv|new[87]	coref|coref|coref|coref	16-4|16-4[106_87]|16-4|16-4[106_87]
13-20	1469-1477	thoracic	object[87]	new[87]	_	_
13-21	1478-1483	aorta	object[87]	new[87]	_	_
13-22	1484-1485	.	_	_	_	_

#Text=These modifications consisted of ( i ) arterial wall hypertrophy , ( ii ) fragmentation , linearization , and refolding of elastic fibers , and ( iii ) impaired contractile and vasorelaxant responses .
14-1	1486-1491	These	abstract[88]	new[88]	_	_
14-2	1492-1505	modifications	abstract[88]	new[88]	_	_
14-3	1506-1515	consisted	_	_	_	_
14-4	1516-1518	of	_	_	_	_
14-5	1519-1520	(	_	_	_	_
14-6	1521-1522	i	_	_	_	_
14-7	1523-1524	)	_	_	_	_
14-8	1525-1533	arterial	substance|abstract[91]	giv|new[91]	appos|coref|appos|coref	14-13[0_91]|27-1|14-13[0_91]|27-1
14-9	1534-1538	wall	object|abstract[91]	giv|new[91]	coref	30-11[214_0]
14-10	1539-1550	hypertrophy	abstract[91]	new[91]	_	_
14-11	1551-1552	,	_	_	_	_
14-12	1553-1554	(	_	_	_	_
14-13	1555-1557	ii	abstract	giv	coref	21-3[147_0]
14-14	1558-1559	)	_	_	_	_
14-15	1560-1573	fragmentation	abstract	giv	coref	16-19
14-16	1574-1575	,	_	_	_	_
14-17	1576-1589	linearization	abstract	new	_	_
14-18	1590-1591	,	_	_	_	_
14-19	1592-1595	and	_	_	_	_
14-20	1596-1605	refolding	event[95]	new[95]	_	_
14-21	1606-1608	of	event[95]	new[95]	_	_
14-22	1609-1616	elastic	event[95]|object[96]	new[95]|new[96]	appos	14-27[0_96]
14-23	1617-1623	fibers	event[95]|object[96]	new[95]|new[96]	_	_
14-24	1624-1625	,	_	_	_	_
14-25	1626-1629	and	_	_	_	_
14-26	1630-1631	(	_	_	_	_
14-27	1632-1635	iii	object	giv	coref	33-6[235_0]
14-28	1636-1637	)	_	_	_	_
14-29	1638-1646	impaired	_	_	_	_
14-30	1647-1658	contractile	abstract[98]	new[98]	coref	18-1[124_98]
14-31	1659-1662	and	abstract[98]	new[98]	_	_
14-32	1663-1675	vasorelaxant	abstract[98]	new[98]	_	_
14-33	1676-1685	responses	abstract[98]	new[98]	_	_
14-34	1686-1687	.	_	_	_	_

#Text=These changes typified the degenerative processes leading to the reduction of compliance and distensibility described in hypertension and associated with aging .
15-1	1688-1693	These	abstract[99]	giv[99]	_	_
15-2	1694-1701	changes	abstract[99]	giv[99]	_	_
15-3	1702-1710	typified	_	_	_	_
15-4	1711-1714	the	abstract[100]	new[100]	_	_
15-5	1715-1727	degenerative	abstract[100]	new[100]	_	_
15-6	1728-1737	processes	abstract[100]	new[100]	_	_
15-7	1738-1745	leading	_	_	_	_
15-8	1746-1748	to	_	_	_	_
15-9	1749-1752	the	abstract[101]	new[101]	coref	34-13[0_101]
15-10	1753-1762	reduction	abstract[101]	new[101]	_	_
15-11	1763-1765	of	abstract[101]	new[101]	_	_
15-12	1766-1776	compliance	abstract[101]|abstract	new[101]|giv	_	_
15-13	1777-1780	and	abstract[101]	new[101]	_	_
15-14	1781-1795	distensibility	abstract[101]|abstract	new[101]|giv	_	_
15-15	1796-1805	described	_	_	_	_
15-16	1806-1808	in	_	_	_	_
15-17	1809-1821	hypertension	abstract	giv	coref	27-29
15-18	1822-1825	and	_	_	_	_
15-19	1826-1836	associated	_	_	_	_
15-20	1837-1841	with	_	_	_	_
15-21	1842-1847	aging	_	_	_	_
15-22	1848-1849	.	_	_	_	_

#Text=Indeed , in SHR aorta , our results showed enlarged internal diameter and media thickening , increased elastin fragmentation ratio , and lower elastin and collagen levels than in normotensive animals .
16-1	1850-1856	Indeed	_	_	_	_
16-2	1857-1858	,	_	_	_	_
16-3	1859-1861	in	_	_	_	_
16-4	1862-1865	SHR	abstract|object[106]	giv|giv[106]	coref|coref|coref|coref	19-18[0_106]|19-20|19-18[0_106]|19-20
16-5	1866-1871	aorta	object[106]	giv[106]	_	_
16-6	1872-1873	,	_	_	_	_
16-7	1874-1877	our	person|abstract[108]	giv|new[108]	ana|coref|ana|coref	24-3|34-3[244_108]|24-3|34-3[244_108]
16-8	1878-1885	results	abstract[108]	new[108]	_	_
16-9	1886-1892	showed	_	_	_	_
16-10	1893-1901	enlarged	quantity[109]	new[109]	_	_
16-11	1902-1910	internal	quantity[109]	new[109]	_	_
16-12	1911-1919	diameter	quantity[109]	new[109]	_	_
16-13	1920-1923	and	_	_	_	_
16-14	1924-1929	media	abstract|abstract[111]	new|new[111]	coref|coref|coref|coref	22-31|33-4[234_111]|22-31|33-4[234_111]
16-15	1930-1940	thickening	abstract[111]	new[111]	_	_
16-16	1941-1942	,	_	_	_	_
16-17	1943-1952	increased	abstract[114]	new[114]	_	_
16-18	1953-1960	elastin	abstract|abstract[114]	giv|new[114]	coref	16-23[115_0]
16-19	1961-1974	fragmentation	abstract|abstract[114]	giv|new[114]	_	_
16-20	1975-1980	ratio	abstract[114]	new[114]	_	_
16-21	1981-1982	,	_	_	_	_
16-22	1983-1986	and	_	_	_	_
16-23	1987-1992	lower	substance[115]	giv[115]	coref	22-4[0_115]
16-24	1993-2000	elastin	substance[115]	giv[115]	_	_
16-25	2001-2004	and	_	_	_	_
16-26	2005-2013	collagen	organization|abstract[117]	new|new[117]	coref|coref	30-19|30-19
16-27	2014-2020	levels	abstract[117]	new[117]	_	_
16-28	2021-2025	than	abstract[117]	new[117]	_	_
16-29	2026-2028	in	abstract[117]	new[117]	_	_
16-30	2029-2041	normotensive	abstract[117]|animal[118]	new[117]|new[118]	coref	26-6[184_118]
16-31	2042-2049	animals	abstract[117]|animal[118]	new[117]|new[118]	_	_
16-32	2050-2051	.	_	_	_	_

#Text=Consequently , contractility was impaired as evidenced by the decreased response and sensitivities to KCl-induced depolarization and PE .
17-1	2052-2064	Consequently	_	_	_	_
17-2	2065-2066	,	_	_	_	_
17-3	2067-2080	contractility	abstract	new	_	_
17-4	2081-2084	was	_	_	_	_
17-5	2085-2093	impaired	_	_	_	_
17-6	2094-2096	as	_	_	_	_
17-7	2097-2106	evidenced	_	_	_	_
17-8	2107-2109	by	_	_	_	_
17-9	2110-2113	the	abstract[120]	new[120]	_	_
17-10	2114-2123	decreased	abstract[120]	new[120]	_	_
17-11	2124-2132	response	abstract[120]	new[120]	_	_
17-12	2133-2136	and	_	_	_	_
17-13	2137-2150	sensitivities	abstract[121]	new[121]	_	_
17-14	2151-2153	to	abstract[121]	new[121]	_	_
17-15	2154-2165	KCl-induced	abstract[121]|abstract[122]	new[121]|new[122]	_	_
17-16	2166-2180	depolarization	abstract[121]|abstract[122]	new[121]|new[122]	_	_
17-17	2181-2184	and	abstract[121]	new[121]	_	_
17-18	2185-2187	PE	abstract[121]|abstract	new[121]|new	_	_
17-19	2188-2189	.	_	_	_	_

#Text=The vasorelaxant responses to both Ach and SNP were also reduced .
18-1	2190-2193	The	abstract[124]	giv[124]	coref	25-1[176_124]
18-2	2194-2206	vasorelaxant	abstract[124]	giv[124]	_	_
18-3	2207-2216	responses	abstract[124]	giv[124]	_	_
18-4	2217-2219	to	abstract[124]	giv[124]	_	_
18-5	2220-2224	both	abstract[124]|abstract[125]	giv[124]|new[125]	_	_
18-6	2225-2228	Ach	abstract[124]|abstract[125]	giv[124]|new[125]	_	_
18-7	2229-2232	and	abstract[124]	giv[124]	_	_
18-8	2233-2236	SNP	abstract[124]|abstract	giv[124]|new	_	_
18-9	2237-2241	were	_	_	_	_
18-10	2242-2246	also	_	_	_	_
18-11	2247-2254	reduced	_	_	_	_
18-12	2255-2256	.	_	_	_	_

#Text=The enhanced effect of L-NAME on PE-induced contraction suggested that the decrease in the vasodilator capacity of aorta in SHR is due to both the alteration of vascular smooth muscle function and NO bioavailability .
19-1	2257-2260	The	abstract[127]	new[127]	coref	28-14[204_127]
19-2	2261-2269	enhanced	abstract[127]	new[127]	_	_
19-3	2270-2276	effect	abstract[127]	new[127]	_	_
19-4	2277-2279	of	abstract[127]	new[127]	_	_
19-5	2280-2286	L-NAME	abstract[127]|substance[128]	new[127]|new[128]	_	_
19-6	2287-2289	on	abstract[127]|substance[128]	new[127]|new[128]	_	_
19-7	2290-2300	PE-induced	abstract[127]|substance[128]|abstract|event[130]	new[127]|new[128]|new|new[130]	_	_
19-8	2301-2312	contraction	abstract[127]|substance[128]|event[130]	new[127]|new[128]|new[130]	_	_
19-9	2313-2322	suggested	_	_	_	_
19-10	2323-2327	that	_	_	_	_
19-11	2328-2331	the	event[131]	new[131]	coref	22-13[155_131]
19-12	2332-2340	decrease	event[131]	new[131]	_	_
19-13	2341-2343	in	event[131]	new[131]	_	_
19-14	2344-2347	the	event[131]|abstract[133]	new[131]|new[133]	_	_
19-15	2348-2359	vasodilator	event[131]|object|abstract[133]	new[131]|new|new[133]	_	_
19-16	2360-2368	capacity	event[131]|abstract[133]	new[131]|new[133]	_	_
19-17	2369-2371	of	event[131]|abstract[133]	new[131]|new[133]	_	_
19-18	2372-2377	aorta	event[131]|abstract[133]|object	new[131]|new[133]|giv	coref	20-19[145_0]
19-19	2378-2380	in	event[131]|abstract[133]	new[131]|new[133]	_	_
19-20	2381-2384	SHR	event[131]|abstract[133]|object	new[131]|new[133]|giv	coref	20-19
19-21	2385-2387	is	_	_	_	_
19-22	2388-2391	due	_	_	_	_
19-23	2392-2394	to	_	_	_	_
19-24	2395-2399	both	abstract[136]	new[136]	_	_
19-25	2400-2403	the	abstract[136]	new[136]	_	_
19-26	2404-2414	alteration	abstract[136]	new[136]	_	_
19-27	2415-2417	of	abstract[136]	new[136]	_	_
19-28	2418-2426	vascular	abstract[136]|abstract[138]	new[136]|giv[138]	coref	24-8[173_138]
19-29	2427-2433	smooth	abstract[136]|abstract[138]	new[136]|giv[138]	_	_
19-30	2434-2440	muscle	abstract[136]|object|abstract[138]	new[136]|new|giv[138]	_	_
19-31	2441-2449	function	abstract[136]|abstract[138]	new[136]|giv[138]	_	_
19-32	2450-2453	and	abstract[136]	new[136]	_	_
19-33	2454-2456	NO	abstract[136]|substance[139]	new[136]|new[139]	coref	25-20[181_139]
19-34	2457-2472	bioavailability	abstract[136]|substance[139]	new[136]|new[139]	_	_
19-35	2473-2474	.	_	_	_	_

#Text=After three months of supplementation , SpSi substantially corrected and even normalized most of the defects identified in SHR aorta .
20-1	2475-2480	After	_	_	_	_
20-2	2481-2486	three	time[140]	new[140]	_	_
20-3	2487-2493	months	time[140]	new[140]	_	_
20-4	2494-2496	of	time[140]	new[140]	_	_
20-5	2497-2512	supplementation	time[140]|substance	new[140]|giv	coref	24-11[175_0]
20-6	2513-2514	,	_	_	_	_
20-7	2515-2519	SpSi	abstract	giv	coref	24-11
20-8	2520-2533	substantially	_	_	_	_
20-9	2534-2543	corrected	_	_	_	_
20-10	2544-2547	and	_	_	_	_
20-11	2548-2552	even	_	_	_	_
20-12	2553-2563	normalized	_	_	_	_
20-13	2564-2568	most	abstract[143]	new[143]	_	_
20-14	2569-2571	of	abstract[143]	new[143]	_	_
20-15	2572-2575	the	abstract[143]	new[143]	_	_
20-16	2576-2583	defects	abstract[143]	new[143]	_	_
20-17	2584-2594	identified	_	_	_	_
20-18	2595-2597	in	_	_	_	_
20-19	2598-2601	SHR	abstract|object[145]	giv|giv[145]	coref|coref	26-6|26-6
20-20	2602-2607	aorta	object[145]	giv[145]	_	_
20-21	2608-2609	.	_	_	_	_

#Text=First , aortic hypertrophy was reduced as shown by morphologic analysis .
21-1	2610-2615	First	_	_	_	_
21-2	2616-2617	,	_	_	_	_
21-3	2618-2624	aortic	abstract|abstract[147]	giv|giv[147]	coref|coref	30-12|30-12
21-4	2625-2636	hypertrophy	abstract[147]	giv[147]	_	_
21-5	2637-2640	was	_	_	_	_
21-6	2641-2648	reduced	_	_	_	_
21-7	2649-2651	as	_	_	_	_
21-8	2652-2657	shown	_	_	_	_
21-9	2658-2660	by	_	_	_	_
21-10	2661-2672	morphologic	abstract[148]	new[148]	_	_
21-11	2673-2681	analysis	abstract[148]	new[148]	_	_
21-12	2682-2683	.	_	_	_	_

#Text=Higher level of elastin fiber density and mRNA level were associated to a decrease in MMP-9 expression , suggesting that both enhanced elastin biosynthesis and reduced extracellular matrix contributed to media thinning .
22-1	2684-2690	Higher	abstract[149]	new[149]	_	_
22-2	2691-2696	level	abstract[149]	new[149]	_	_
22-3	2697-2699	of	abstract[149]	new[149]	_	_
22-4	2700-2707	elastin	abstract[149]|substance|abstract[152]	new[149]|giv|new[152]	coref|coref	22-23|22-23
22-5	2708-2713	fiber	abstract[149]|substance|abstract[152]	new[149]|new|new[152]	coref	38-15
22-6	2714-2721	density	abstract[149]|abstract[152]	new[149]|new[152]	_	_
22-7	2722-2725	and	abstract[149]	new[149]	_	_
22-8	2726-2730	mRNA	abstract[149]|place|abstract[154]	new[149]|new|new[154]	coref|coref	40-5[283_154]|40-5[283_154]
22-9	2731-2736	level	abstract[149]|abstract[154]	new[149]|new[154]	_	_
22-10	2737-2741	were	_	_	_	_
22-11	2742-2752	associated	_	_	_	_
22-12	2753-2755	to	_	_	_	_
22-13	2756-2757	a	event[155]	giv[155]	_	_
22-14	2758-2766	decrease	event[155]	giv[155]	_	_
22-15	2767-2769	in	event[155]	giv[155]	_	_
22-16	2770-2775	MMP-9	event[155]|person|abstract[157]	giv[155]|new|new[157]	_	_
22-17	2776-2786	expression	event[155]|abstract[157]	giv[155]|new[157]	_	_
22-18	2787-2788	,	_	_	_	_
22-19	2789-2799	suggesting	_	_	_	_
22-20	2800-2804	that	_	_	_	_
22-21	2805-2809	both	abstract[159]	new[159]	_	_
22-22	2810-2818	enhanced	abstract[159]	new[159]	_	_
22-23	2819-2826	elastin	substance|abstract[159]	giv|new[159]	coref	30-17
22-24	2827-2839	biosynthesis	abstract[159]	new[159]	_	_
22-25	2840-2843	and	_	_	_	_
22-26	2844-2851	reduced	abstract[160]	new[160]	coref	23-13[167_160]
22-27	2852-2865	extracellular	abstract[160]	new[160]	_	_
22-28	2866-2872	matrix	abstract[160]	new[160]	_	_
22-29	2873-2884	contributed	_	_	_	_
22-30	2885-2887	to	_	_	_	_
22-31	2888-2893	media	abstract|abstract[162]	giv|new[162]	ana|ana	23-1[0_162]|23-1[0_162]
22-32	2894-2902	thinning	abstract[162]	new[162]	_	_
22-33	2903-2904	.	_	_	_	_

#Text=It is known that hypertensive vascular remodeling involves reorganization and impairment of the extracellular matrix and that MMPs play an important role in this remodeling .
23-1	2905-2907	It	abstract	giv	_	_
23-2	2908-2910	is	_	_	_	_
23-3	2911-2916	known	_	_	_	_
23-4	2917-2921	that	_	_	_	_
23-5	2922-2934	hypertensive	event[164]	giv[164]	coref	23-24[170_164]
23-6	2935-2943	vascular	event[164]	giv[164]	_	_
23-7	2944-2954	remodeling	event[164]	giv[164]	_	_
23-8	2955-2963	involves	_	_	_	_
23-9	2964-2978	reorganization	event	new	_	_
23-10	2979-2982	and	_	_	_	_
23-11	2983-2993	impairment	event[166]	new[166]	_	_
23-12	2994-2996	of	event[166]	new[166]	_	_
23-13	2997-3000	the	event[166]|abstract[167]	new[166]|giv[167]	_	_
23-14	3001-3014	extracellular	event[166]|abstract[167]	new[166]|giv[167]	_	_
23-15	3015-3021	matrix	event[166]|abstract[167]	new[166]|giv[167]	_	_
23-16	3022-3025	and	_	_	_	_
23-17	3026-3030	that	_	_	_	_
23-18	3031-3035	MMPs	abstract	new	_	_
23-19	3036-3040	play	_	_	_	_
23-20	3041-3043	an	abstract[169]	giv[169]	_	_
23-21	3044-3053	important	abstract[169]	giv[169]	_	_
23-22	3054-3058	role	abstract[169]	giv[169]	_	_
23-23	3059-3061	in	abstract[169]	giv[169]	_	_
23-24	3062-3066	this	abstract[169]|event[170]	giv[169]|giv[170]	_	_
23-25	3067-3077	remodeling	abstract[169]|event[170]	giv[169]|giv[170]	_	_
23-26	3078-3079	.	_	_	_	_

#Text=Second , we observed an improvement of vascular function after SpSi supplementation .
24-1	3080-3086	Second	_	_	_	_
24-2	3087-3088	,	_	_	_	_
24-3	3089-3091	we	person	giv	ana	26-3
24-4	3092-3100	observed	_	_	_	_
24-5	3101-3103	an	abstract[172]	new[172]	_	_
24-6	3104-3115	improvement	abstract[172]	new[172]	_	_
24-7	3116-3118	of	abstract[172]	new[172]	_	_
24-8	3119-3127	vascular	abstract[172]|abstract[173]	new[172]|giv[173]	coref	36-15[261_173]
24-9	3128-3136	function	abstract[172]|abstract[173]	new[172]|giv[173]	_	_
24-10	3137-3142	after	_	_	_	_
24-11	3143-3147	SpSi	substance|substance[175]	giv|giv[175]	coref|coref|coref|coref	26-10|27-36[0_175]|26-10|27-36[0_175]
24-12	3148-3163	supplementation	substance[175]	giv[175]	_	_
24-13	3164-3165	.	_	_	_	_

#Text=Contractile and vasorelaxant responses were increased in association with an increased sensitivity to the agonists and antagonists tested and a better NO bioavailability .
25-1	3166-3177	Contractile	abstract[176]	giv[176]	_	_
25-2	3178-3181	and	abstract[176]	giv[176]	_	_
25-3	3182-3194	vasorelaxant	abstract[176]	giv[176]	_	_
25-4	3195-3204	responses	abstract[176]	giv[176]	_	_
25-5	3205-3209	were	_	_	_	_
25-6	3210-3219	increased	_	_	_	_
25-7	3220-3222	in	_	_	_	_
25-8	3223-3234	association	abstract	new	_	_
25-9	3235-3239	with	_	_	_	_
25-10	3240-3242	an	abstract[178]	new[178]	_	_
25-11	3243-3252	increased	abstract[178]	new[178]	_	_
25-12	3253-3264	sensitivity	abstract[178]	new[178]	_	_
25-13	3265-3267	to	abstract[178]	new[178]	_	_
25-14	3268-3271	the	abstract[178]|abstract[179]	new[178]|new[179]	_	_
25-15	3272-3280	agonists	abstract[178]|abstract[179]	new[178]|new[179]	_	_
25-16	3281-3284	and	abstract[178]	new[178]	_	_
25-17	3285-3296	antagonists	abstract[178]|person	new[178]|new	_	_
25-18	3297-3303	tested	_	_	_	_
25-19	3304-3307	and	_	_	_	_
25-20	3308-3309	a	substance[181]	giv[181]	_	_
25-21	3310-3316	better	substance[181]	giv[181]	_	_
25-22	3317-3319	NO	substance[181]	giv[181]	_	_
25-23	3320-3335	bioavailability	substance[181]	giv[181]	_	_
25-24	3336-3337	.	_	_	_	_

#Text=Finally , we found that SHR animals supplemented with SpSi had lower arterial pressure than control SHR .
26-1	3338-3345	Finally	_	_	_	_
26-2	3346-3347	,	_	_	_	_
26-3	3348-3350	we	person	giv	ana	27-25
26-4	3351-3356	found	_	_	_	_
26-5	3357-3361	that	_	_	_	_
26-6	3362-3365	SHR	object|animal[184]	giv|giv[184]	coref|coref	26-16[187_0]|26-16[187_0]
26-7	3366-3373	animals	animal[184]	giv[184]	_	_
26-8	3374-3386	supplemented	_	_	_	_
26-9	3387-3391	with	_	_	_	_
26-10	3392-3396	SpSi	substance	giv	coref	28-24
26-11	3397-3400	had	_	_	_	_
26-12	3401-3406	lower	abstract[186]	new[186]	coref	27-1[189_186]
26-13	3407-3415	arterial	abstract[186]	new[186]	_	_
26-14	3416-3424	pressure	abstract[186]	new[186]	_	_
26-15	3425-3429	than	abstract[186]	new[186]	_	_
26-16	3430-3437	control	abstract[186]|object[187]	new[186]|giv[187]	coref	28-17[0_187]
26-17	3438-3441	SHR	abstract[186]|object[187]	new[186]|giv[187]	_	_
26-18	3442-3443	.	_	_	_	_

#Text=Arterial pressure , although significantly reduced , was still higher than normal pressure which may explain the lack of benefit on cardiac parameters in our experimental conditions ( hypertension already established , 3 months of supplementation ) .
27-1	3444-3452	Arterial	substance|abstract[189]	giv|giv[189]	coref|coref	27-12[190_189]|27-12[190_189]
27-2	3453-3461	pressure	abstract[189]	giv[189]	_	_
27-3	3462-3463	,	_	_	_	_
27-4	3464-3472	although	_	_	_	_
27-5	3473-3486	significantly	_	_	_	_
27-6	3487-3494	reduced	_	_	_	_
27-7	3495-3496	,	_	_	_	_
27-8	3497-3500	was	_	_	_	_
27-9	3501-3506	still	_	_	_	_
27-10	3507-3513	higher	_	_	_	_
27-11	3514-3518	than	_	_	_	_
27-12	3519-3525	normal	abstract[190]	giv[190]	coref	34-15[248_190]
27-13	3526-3534	pressure	abstract[190]	giv[190]	_	_
27-14	3535-3540	which	_	_	_	_
27-15	3541-3544	may	_	_	_	_
27-16	3545-3552	explain	_	_	_	_
27-17	3553-3556	the	abstract[191]	new[191]	_	_
27-18	3557-3561	lack	abstract[191]	new[191]	_	_
27-19	3562-3564	of	abstract[191]	new[191]	_	_
27-20	3565-3572	benefit	abstract[191]|abstract[192]	new[191]|new[192]	coref	38-23[277_192]
27-21	3573-3575	on	abstract[191]|abstract[192]	new[191]|new[192]	_	_
27-22	3576-3583	cardiac	abstract[191]|abstract[192]|abstract[193]	new[191]|new[192]|new[193]	_	_
27-23	3584-3594	parameters	abstract[191]|abstract[192]|abstract[193]	new[191]|new[192]|new[193]	_	_
27-24	3595-3597	in	abstract[191]|abstract[192]|abstract[193]	new[191]|new[192]|new[193]	_	_
27-25	3598-3601	our	abstract[191]|abstract[192]|abstract[193]|person|abstract[195]	new[191]|new[192]|new[193]|giv|new[195]	ana|ana	28-5|28-5
27-26	3602-3614	experimental	abstract[191]|abstract[192]|abstract[193]|abstract[195]	new[191]|new[192]|new[193]|new[195]	_	_
27-27	3615-3625	conditions	abstract[191]|abstract[192]|abstract[193]|abstract[195]	new[191]|new[192]|new[193]|new[195]	_	_
27-28	3626-3627	(	_	_	_	_
27-29	3628-3640	hypertension	abstract	giv	_	_
27-30	3641-3648	already	_	_	_	_
27-31	3649-3660	established	_	_	_	_
27-32	3661-3662	,	_	_	_	_
27-33	3663-3664	3	time[197]	new[197]	_	_
27-34	3665-3671	months	time[197]	new[197]	_	_
27-35	3672-3674	of	time[197]	new[197]	_	_
27-36	3675-3690	supplementation	time[197]|substance	new[197]|giv	coref	28-9[202_0]
27-37	3691-3692	)	_	_	_	_
27-38	3693-3694	.	_	_	_	_

#Text=Another interesting result in our study is that supplementation with Sp alone had no effect in SHR suggesting that the benefits observed with SpSi are genuine effects of Si .
28-1	3695-3702	Another	abstract[199]	new[199]	coref	38-3[270_199]
28-2	3703-3714	interesting	abstract[199]	new[199]	_	_
28-3	3715-3721	result	abstract[199]	new[199]	_	_
28-4	3722-3724	in	abstract[199]	new[199]	_	_
28-5	3725-3728	our	abstract[199]|person|abstract[201]	new[199]|giv|new[201]	ana|coref|ana|coref	34-3|34-9[245_201]|34-3|34-9[245_201]
28-6	3729-3734	study	abstract[199]|abstract[201]	new[199]|new[201]	_	_
28-7	3735-3737	is	_	_	_	_
28-8	3738-3742	that	_	_	_	_
28-9	3743-3758	supplementation	substance[202]	giv[202]	coref	33-15[239_202]
28-10	3759-3763	with	substance[202]	giv[202]	_	_
28-11	3764-3766	Sp	substance[202]|substance	giv[202]|giv	_	_
28-12	3767-3772	alone	_	_	_	_
28-13	3773-3776	had	_	_	_	_
28-14	3777-3779	no	abstract[204]	giv[204]	coref	39-13[280_204]
28-15	3780-3786	effect	abstract[204]	giv[204]	_	_
28-16	3787-3789	in	abstract[204]	giv[204]	_	_
28-17	3790-3793	SHR	abstract[204]|abstract	giv[204]|giv	coref	34-24
28-18	3794-3804	suggesting	_	_	_	_
28-19	3805-3809	that	_	_	_	_
28-20	3810-3813	the	abstract[206]	new[206]	_	_
28-21	3814-3822	benefits	abstract[206]	new[206]	_	_
28-22	3823-3831	observed	_	_	_	_
28-23	3832-3836	with	_	_	_	_
28-24	3837-3841	SpSi	substance	giv	coref	38-11
28-25	3842-3845	are	_	_	_	_
28-26	3846-3853	genuine	abstract[208]	new[208]	_	_
28-27	3854-3861	effects	abstract[208]	new[208]	_	_
28-28	3862-3864	of	abstract[208]	new[208]	_	_
28-29	3865-3867	Si	abstract[208]|abstract	new[208]|giv	coref	29-5
28-30	3868-3869	.	_	_	_	_

#Text=The nutritional essentiality of Si is undeniable .
29-1	3870-3873	The	abstract[210]	new[210]	_	_
29-2	3874-3885	nutritional	abstract[210]	new[210]	_	_
29-3	3886-3898	essentiality	abstract[210]	new[210]	_	_
29-4	3899-3901	of	abstract[210]	new[210]	_	_
29-5	3902-3904	Si	abstract[210]|person	new[210]|giv	coref	31-9[223_0]
29-6	3905-3907	is	_	_	_	_
29-7	3908-3918	undeniable	_	_	_	_
29-8	3919-3920	.	_	_	_	_

#Text=This organic element appears as an important structural component of the aortic wall which contributes to elastin and collagen synthesis and stability .
30-1	3921-3925	This	substance[212]	new[212]	_	_
30-2	3926-3933	organic	substance[212]	new[212]	_	_
30-3	3934-3941	element	substance[212]	new[212]	_	_
30-4	3942-3949	appears	_	_	_	_
30-5	3950-3952	as	_	_	_	_
30-6	3953-3955	an	_	_	_	_
30-7	3956-3965	important	_	_	_	_
30-8	3966-3976	structural	_	_	_	_
30-9	3977-3986	component	_	_	_	_
30-10	3987-3989	of	_	_	_	_
30-11	3990-3993	the	object[214]	giv[214]	coref	33-11[237_214]
30-12	3994-4000	aortic	place|object[214]	giv|giv[214]	coref	33-12
30-13	4001-4005	wall	object[214]	giv[214]	_	_
30-14	4006-4011	which	_	_	_	_
30-15	4012-4023	contributes	_	_	_	_
30-16	4024-4026	to	_	_	_	_
30-17	4027-4034	elastin	substance	giv	_	_
30-18	4035-4038	and	_	_	_	_
30-19	4039-4047	collagen	organization|abstract[217]	giv|new[217]	_	_
30-20	4048-4057	synthesis	abstract[217]	new[217]	_	_
30-21	4058-4061	and	_	_	_	_
30-22	4062-4071	stability	abstract	new	_	_
30-23	4072-4073	.	_	_	_	_

#Text=Data from animal and human studies demonstrated that dietary Si mitigates the risk of cardiovascular diseases .
31-1	4074-4078	Data	abstract[219]	new[219]	_	_
31-2	4079-4083	from	abstract[219]	new[219]	_	_
31-3	4084-4090	animal	abstract[219]|animal	new[219]|new	_	_
31-4	4091-4094	and	abstract[219]	new[219]	_	_
31-5	4095-4100	human	abstract[219]|event[221]	new[219]|new[221]	_	_
31-6	4101-4108	studies	abstract[219]|event[221]	new[219]|new[221]	_	_
31-7	4109-4121	demonstrated	_	_	_	_
31-8	4122-4126	that	_	_	_	_
31-9	4127-4134	dietary	abstract|person[223]	new|giv[223]	coref|coref	32-1[0_223]|32-1[0_223]
31-10	4135-4137	Si	person[223]	giv[223]	_	_
31-11	4138-4147	mitigates	_	_	_	_
31-12	4148-4151	the	abstract[224]	new[224]	_	_
31-13	4152-4156	risk	abstract[224]	new[224]	_	_
31-14	4157-4159	of	abstract[224]	new[224]	_	_
31-15	4160-4174	cardiovascular	abstract[224]|abstract[225]	new[224]|new[225]	coref	32-14[231_225]
31-16	4175-4183	diseases	abstract[224]|abstract[225]	new[224]|new[225]	_	_
31-17	4184-4185	.	_	_	_	_

#Text=Si in drinking water has been inversely correlated with mortality rates due to coronary heart diseases in Finland .
32-1	4186-4188	Si	person	giv	coref	36-9
32-2	4189-4191	in	_	_	_	_
32-3	4192-4200	drinking	_	_	_	_
32-4	4201-4206	water	substance	new	_	_
32-5	4207-4210	has	_	_	_	_
32-6	4211-4215	been	_	_	_	_
32-7	4216-4225	inversely	_	_	_	_
32-8	4226-4236	correlated	_	_	_	_
32-9	4237-4241	with	_	_	_	_
32-10	4242-4251	mortality	abstract[228]	new[228]	_	_
32-11	4252-4257	rates	abstract[228]	new[228]	_	_
32-12	4258-4261	due	_	_	_	_
32-13	4262-4264	to	_	_	_	_
32-14	4265-4273	coronary	object|abstract[231]	new|giv[231]	_	_
32-15	4274-4279	heart	object|abstract[231]	new|giv[231]	_	_
32-16	4280-4288	diseases	abstract[231]	giv[231]	_	_
32-17	4289-4291	in	abstract[231]	giv[231]	_	_
32-18	4292-4299	Finland	abstract[231]|place	giv[231]|new	_	_
32-19	4300-4301	.	_	_	_	_

#Text=Reduced damage and thickening of elastic fibers were observed in the aortic wall after silicon supplementation in rabbit models of diet-induced atherosclerosis .
33-1	4302-4309	Reduced	abstract[233]	new[233]	_	_
33-2	4310-4316	damage	abstract[233]	new[233]	_	_
33-3	4317-4320	and	_	_	_	_
33-4	4321-4331	thickening	abstract[234]	giv[234]	_	_
33-5	4332-4334	of	abstract[234]	giv[234]	_	_
33-6	4335-4342	elastic	abstract[234]|object[235]	giv[234]|giv[235]	_	_
33-7	4343-4349	fibers	abstract[234]|object[235]	giv[234]|giv[235]	_	_
33-8	4350-4354	were	_	_	_	_
33-9	4355-4363	observed	_	_	_	_
33-10	4364-4366	in	_	_	_	_
33-11	4367-4370	the	object[237]	giv[237]	coref	39-6[279_237]
33-12	4371-4377	aortic	place|object[237]	giv|giv[237]	coref	40-9
33-13	4378-4382	wall	object[237]	giv[237]	_	_
33-14	4383-4388	after	_	_	_	_
33-15	4389-4396	silicon	substance|substance[239]	new|giv[239]	coref|coref|coref|coref	34-19[249_239]|34-21[250_0]|34-19[249_239]|34-21[250_0]
33-16	4397-4412	supplementation	substance[239]	giv[239]	_	_
33-17	4413-4415	in	substance[239]	giv[239]	_	_
33-18	4416-4422	rabbit	substance[239]|animal|abstract[241]	giv[239]|new|new[241]	_	_
33-19	4423-4429	models	substance[239]|abstract[241]	giv[239]|new[241]	_	_
33-20	4430-4432	of	substance[239]|abstract[241]	giv[239]|new[241]	_	_
33-21	4433-4445	diet-induced	substance[239]|abstract[241]|abstract[242]	giv[239]|new[241]|new[242]	_	_
33-22	4446-4461	atherosclerosis	substance[239]|abstract[241]|abstract[242]	giv[239]|new[241]|new[242]	_	_
33-23	4462-4463	.	_	_	_	_

#Text=Moreover , our results are in line with a previous study reporting reduction in systolic arterial pressure after supplementation with soluble silicon in SHR .
34-1	4464-4472	Moreover	_	_	_	_
34-2	4473-4474	,	_	_	_	_
34-3	4475-4478	our	person|abstract[244]	giv|giv[244]	ana|ana	36-6|36-6
34-4	4479-4486	results	abstract[244]	giv[244]	_	_
34-5	4487-4490	are	_	_	_	_
34-6	4491-4493	in	_	_	_	_
34-7	4494-4498	line	_	_	_	_
34-8	4499-4503	with	_	_	_	_
34-9	4504-4505	a	abstract[245]	giv[245]	coref	35-2[252_245]
34-10	4506-4514	previous	abstract[245]	giv[245]	_	_
34-11	4515-4520	study	abstract[245]	giv[245]	_	_
34-12	4521-4530	reporting	_	_	_	_
34-13	4531-4540	reduction	abstract	giv	_	_
34-14	4541-4543	in	_	_	_	_
34-15	4544-4552	systolic	person|abstract[248]	new|giv[248]	_	_
34-16	4553-4561	arterial	abstract[248]	giv[248]	_	_
34-17	4562-4570	pressure	abstract[248]	giv[248]	_	_
34-18	4571-4576	after	abstract[248]	giv[248]	_	_
34-19	4577-4592	supplementation	abstract[248]|substance[249]	giv[248]|giv[249]	coref	38-11[274_249]
34-20	4593-4597	with	abstract[248]|substance[249]	giv[248]|giv[249]	_	_
34-21	4598-4605	soluble	abstract[248]|substance[249]|substance[250]	giv[248]|giv[249]|giv[250]	_	_
34-22	4606-4613	silicon	abstract[248]|substance[249]|substance[250]	giv[248]|giv[249]|giv[250]	_	_
34-23	4614-4616	in	abstract[248]|substance[249]|substance[250]	giv[248]|giv[249]|giv[250]	_	_
34-24	4617-4620	SHR	abstract[248]|substance[249]|substance[250]|substance	giv[248]|giv[249]|giv[250]|giv	_	_
34-25	4621-4622	.	_	_	_	_

#Text=In that study , arterial structure was not investigated and enhancement of intracellular magnesium uptake was evoked as a possible mechanism .
35-1	4623-4625	In	_	_	_	_
35-2	4626-4630	that	abstract[252]	giv[252]	coref	38-7[272_252]
35-3	4631-4636	study	abstract[252]	giv[252]	_	_
35-4	4637-4638	,	_	_	_	_
35-5	4639-4647	arterial	abstract[253]	new[253]	_	_
35-6	4648-4657	structure	abstract[253]	new[253]	_	_
35-7	4658-4661	was	_	_	_	_
35-8	4662-4665	not	_	_	_	_
35-9	4666-4678	investigated	_	_	_	_
35-10	4679-4682	and	_	_	_	_
35-11	4683-4694	enhancement	abstract[254]	new[254]	_	_
35-12	4695-4697	of	abstract[254]	new[254]	_	_
35-13	4698-4711	intracellular	abstract[254]|abstract[256]	new[254]|new[256]	ana	36-1[0_256]
35-14	4712-4721	magnesium	abstract[254]|substance|abstract[256]	new[254]|new|new[256]	coref	36-30
35-15	4722-4728	uptake	abstract[254]|abstract[256]	new[254]|new[256]	_	_
35-16	4729-4732	was	_	_	_	_
35-17	4733-4739	evoked	_	_	_	_
35-18	4740-4742	as	_	_	_	_
35-19	4743-4744	a	_	_	_	_
35-20	4745-4753	possible	_	_	_	_
35-21	4754-4763	mechanism	_	_	_	_
35-22	4764-4765	.	_	_	_	_

#Text=This is not inconsistent with our findings as Si is supposed to contribute to biological function and affect retention or function of other minerals , such as aluminum or magnesium .
36-1	4766-4770	This	abstract	giv	_	_
36-2	4771-4773	is	_	_	_	_
36-3	4774-4777	not	_	_	_	_
36-4	4778-4790	inconsistent	_	_	_	_
36-5	4791-4795	with	_	_	_	_
36-6	4796-4799	our	person|abstract[259]	giv|new[259]	ana|ana	38-7|38-7
36-7	4800-4808	findings	abstract[259]	new[259]	_	_
36-8	4809-4811	as	_	_	_	_
36-9	4812-4814	Si	substance	giv	coref	37-11
36-10	4815-4817	is	_	_	_	_
36-11	4818-4826	supposed	_	_	_	_
36-12	4827-4829	to	_	_	_	_
36-13	4830-4840	contribute	_	_	_	_
36-14	4841-4843	to	_	_	_	_
36-15	4844-4854	biological	abstract[261]	giv[261]	_	_
36-16	4855-4863	function	abstract[261]	giv[261]	_	_
36-17	4864-4867	and	_	_	_	_
36-18	4868-4874	affect	_	_	_	_
36-19	4875-4884	retention	abstract	new	_	_
36-20	4885-4887	or	_	_	_	_
36-21	4888-4896	function	abstract[263]	new[263]	_	_
36-22	4897-4899	of	abstract[263]	new[263]	_	_
36-23	4900-4905	other	abstract[263]|substance[264]	new[263]|new[264]	_	_
36-24	4906-4914	minerals	abstract[263]|substance[264]	new[263]|new[264]	_	_
36-25	4915-4916	,	abstract[263]|substance[264]	new[263]|new[264]	_	_
36-26	4917-4921	such	abstract[263]|substance[264]	new[263]|new[264]	_	_
36-27	4922-4924	as	abstract[263]|substance[264]	new[263]|new[264]	_	_
36-28	4925-4933	aluminum	abstract[263]|substance[264]|substance	new[263]|new[264]|new	_	_
36-29	4934-4936	or	abstract[263]|substance[264]	new[263]|new[264]	_	_
36-30	4937-4946	magnesium	abstract[263]|substance[264]|substance	new[263]|new[264]|giv	_	_
36-31	4947-4948	.	_	_	_	_

#Text=Various mechanisms are potentially involved in the beneficial effects of Si .
37-1	4949-4956	Various	abstract[267]	new[267]	_	_
37-2	4957-4967	mechanisms	abstract[267]	new[267]	_	_
37-3	4968-4971	are	_	_	_	_
37-4	4972-4983	potentially	_	_	_	_
37-5	4984-4992	involved	_	_	_	_
37-6	4993-4995	in	_	_	_	_
37-7	4996-4999	the	abstract[268]	new[268]	_	_
37-8	5000-5010	beneficial	abstract[268]	new[268]	_	_
37-9	5011-5018	effects	abstract[268]	new[268]	_	_
37-10	5019-5021	of	abstract[268]	new[268]	_	_
37-11	5022-5024	Si	abstract[268]|substance	new[268]|giv	coref	40-5
37-12	5025-5026	.	_	_	_	_

#Text=Here , a major result in our study is that SpSi supplementation reverses elastic fiber degradation which is likely to contribute to the overall benefit .
38-1	5027-5031	Here	_	_	_	_
38-2	5032-5033	,	_	_	_	_
38-3	5034-5035	a	abstract[270]	giv[270]	_	_
38-4	5036-5041	major	abstract[270]	giv[270]	_	_
38-5	5042-5048	result	abstract[270]	giv[270]	_	_
38-6	5049-5051	in	abstract[270]	giv[270]	_	_
38-7	5052-5055	our	abstract[270]|person|abstract[272]	giv[270]|giv|giv[272]	_	_
38-8	5056-5061	study	abstract[270]|abstract[272]	giv[270]|giv[272]	_	_
38-9	5062-5064	is	_	_	_	_
38-10	5065-5069	that	_	_	_	_
38-11	5070-5074	SpSi	substance|substance[274]	giv|giv[274]	_	_
38-12	5075-5090	supplementation	substance[274]	giv[274]	_	_
38-13	5091-5099	reverses	_	_	_	_
38-14	5100-5107	elastic	abstract[276]	new[276]	_	_
38-15	5108-5113	fiber	substance|abstract[276]	giv|new[276]	_	_
38-16	5114-5125	degradation	abstract[276]	new[276]	_	_
38-17	5126-5131	which	_	_	_	_
38-18	5132-5134	is	_	_	_	_
38-19	5135-5141	likely	_	_	_	_
38-20	5142-5144	to	_	_	_	_
38-21	5145-5155	contribute	_	_	_	_
38-22	5156-5158	to	_	_	_	_
38-23	5159-5162	the	abstract[277]	giv[277]	_	_
38-24	5163-5170	overall	abstract[277]	giv[277]	_	_
38-25	5171-5178	benefit	abstract[277]	giv[277]	_	_
38-26	5179-5180	.	_	_	_	_

#Text=The observed regenerative changes of the vascular wall are in line with a Si-related beneficial effect .
39-1	5181-5184	The	abstract[278]	new[278]	_	_
39-2	5185-5193	observed	abstract[278]	new[278]	_	_
39-3	5194-5206	regenerative	abstract[278]	new[278]	_	_
39-4	5207-5214	changes	abstract[278]	new[278]	_	_
39-5	5215-5217	of	abstract[278]	new[278]	_	_
39-6	5218-5221	the	abstract[278]|object[279]	new[278]|giv[279]	_	_
39-7	5222-5230	vascular	abstract[278]|object[279]	new[278]|giv[279]	_	_
39-8	5231-5235	wall	abstract[278]|object[279]	new[278]|giv[279]	_	_
39-9	5236-5239	are	_	_	_	_
39-10	5240-5242	in	_	_	_	_
39-11	5243-5247	line	_	_	_	_
39-12	5248-5252	with	_	_	_	_
39-13	5253-5254	a	abstract[280]	giv[280]	_	_
39-14	5255-5265	Si-related	abstract[280]	giv[280]	_	_
39-15	5266-5276	beneficial	abstract[280]	giv[280]	_	_
39-16	5277-5283	effect	abstract[280]	giv[280]	_	_
39-17	5284-5285	.	_	_	_	_

#Text=However , quantification of Si level in the aortic tissue is warranted to validate this hypothesis .
40-1	5286-5293	However	_	_	_	_
40-2	5294-5295	,	_	_	_	_
40-3	5296-5310	quantification	abstract[281]	new[281]	_	_
40-4	5311-5313	of	abstract[281]	new[281]	_	_
40-5	5314-5316	Si	abstract[281]|person|abstract[283]	new[281]|giv|giv[283]	_	_
40-6	5317-5322	level	abstract[281]|abstract[283]	new[281]|giv[283]	_	_
40-7	5323-5325	in	abstract[281]|abstract[283]	new[281]|giv[283]	_	_
40-8	5326-5329	the	abstract[281]|abstract[283]|object[285]	new[281]|giv[283]|new[285]	_	_
40-9	5330-5336	aortic	abstract[281]|abstract[283]|abstract|object[285]	new[281]|giv[283]|giv|new[285]	_	_
40-10	5337-5343	tissue	abstract[281]|abstract[283]|object[285]	new[281]|giv[283]|new[285]	_	_
40-11	5344-5346	is	_	_	_	_
40-12	5347-5356	warranted	_	_	_	_
40-13	5357-5359	to	_	_	_	_
40-14	5360-5368	validate	_	_	_	_
40-15	5369-5373	this	abstract[286]	new[286]	_	_
40-16	5374-5384	hypothesis	abstract[286]	new[286]	_	_
40-17	5385-5386	.	_	_	_	_
